Sun Yat-sen University: Carcinoma, Squamous Cell trials

The registry lists 25 Carcinoma, Squamous Cell studies with Sun Yat-sen University as lead sponsor. 11 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 16Phase 3 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal CancerNot yet recruitingNCT06861712Phase 2
• SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and HypopharynxRecruitingNCT06611137Phase 2
• Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)RecruitingNCT06561178
• BAI-BACE for Advanced Lung Squamous Cell CarcinomaRecruitingNCT06377735Not applicable
• SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and OropharynxRecruitingNCT06219980Phase 2
• Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)RecruitingNCT06187597Phase 2
• PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCCRecruitingNCT05737563Phase 3
• Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCCRecruitingNCT05626569Phase 2
• Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）RecruitingNCT05512520Phase 2
• Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)RecruitingNCT05044117Phase 3
• Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And NeckRecruitingNCT03830385Phase 2
• A Clinical Trial of Esophagectomy for Esophageal CarcinomaCompletedNCT06691503Phase 2
• Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant ChemoradiotherapyActive, not recruitingNCT06061263
• Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)Active, not recruitingNCT05520619Phase 2
• Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04844385Phase 2
• Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell CarcinomaCompletedNCT04380480Phase 2
• Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell CarcinomaCompletedNCT03660449Phase 2
• Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT02964455Phase 1
• A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell CarcinomaStatus unknownNCT02915965Phase 2
• Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.CompletedNCT02606916Phase 2
• Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)Active, not recruitingNCT02465736Phase 3
• Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal CancerStatus unknownNCT02325986Phase 2
• Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell CarcinomaStatus unknownNCT01334320Not applicable
• Improve the Treatment of Thoracic Esophageal CancerCompletedNCT01137123Phase 3
• Trial of E10A in Head and Neck CancerStatus unknownNCT00634595Phase 2